TW200936570A - 2-aminopyrimidine derivatives - Google Patents

2-aminopyrimidine derivatives Download PDF

Info

Publication number: TW200936570A
Authority: TW; Taiwan
Prior art keywords: group; amine; compound; methylamino; formula
Prior art date: 2007-11-30

Application number

TW097145757A

Other languages

English (en)

Chinese (zh)

Inventor

Gonzalez Elena Carceller

Fuentes Eva Maria Medina

Via Josep Marti

Bernado Marina Virgili

Original Assignee

Palau Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-30

Filing date

2008-11-26

Publication date

2009-09-01

2008-11-26 Application filed by Palau Pharma Sa filed Critical Palau Pharma Sa

2009-09-01 Publication of TW200936570A publication Critical patent/TW200936570A/zh

Links

150000005006 2-aminopyrimidines Chemical class 0.000 title abstract description 3
150000001875 compounds Chemical class 0.000 claims abstract description 369
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 217
125000000217 alkyl group Chemical group 0.000 claims description 193
125000000623 heterocyclic group Chemical group 0.000 claims description 178
125000004433 nitrogen atom Chemical group N* 0.000 claims description 139
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 112
-1 4-cyclopropylmethyl-6-(3-(methylamino)azol-1-yl)pyrimidine-2-amine Chemical compound 0.000 claims description 87
LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims description 83
238000000034 method Methods 0.000 claims description 62
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 57
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 54
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 49
229910003827 NRaRb Inorganic materials 0.000 claims description 48
125000002619 bicyclic group Chemical group 0.000 claims description 46
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 45
150000003839 salts Chemical class 0.000 claims description 44
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 40
125000005842 heteroatom Chemical group 0.000 claims description 33
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 31
125000001424 substituent group Chemical group 0.000 claims description 29
208000026935 allergic disease Diseases 0.000 claims description 26
208000002193 Pain Diseases 0.000 claims description 24
238000011282 treatment Methods 0.000 claims description 24
230000000172 allergic effect Effects 0.000 claims description 23
201000010099 disease Diseases 0.000 claims description 23
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
208000026278 immune system disease Diseases 0.000 claims description 23
208000027866 inflammatory disease Diseases 0.000 claims description 23
125000002950 monocyclic group Chemical group 0.000 claims description 23
150000001412 amines Chemical class 0.000 claims description 20
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
125000004429 atom Chemical group 0.000 claims description 18
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 17
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 16
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 15
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical group [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 15
229910052707 ruthenium Inorganic materials 0.000 claims description 15
230000001900 immune effect Effects 0.000 claims description 14
229910052757 nitrogen Inorganic materials 0.000 claims description 14
230000001404 mediated effect Effects 0.000 claims description 13
125000000753 cycloalkyl group Chemical group 0.000 claims description 12
102000004187 Histamine H4 receptors Human genes 0.000 claims description 10
108090000796 Histamine H4 receptors Proteins 0.000 claims description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
102000000543 Histamine Receptors Human genes 0.000 claims description 9
108010002059 Histamine Receptors Proteins 0.000 claims description 9
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 9
125000003386 piperidinyl group Chemical group 0.000 claims description 9
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 8
125000001153 fluoro group Chemical group F* 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims description 5
125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 5
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 5
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
125000004076 pyridyl group Chemical group 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
125000004122 cyclic group Chemical group 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 4
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
PCNMGQFUWWCGND-JTQLQIEISA-N 4-(2,2-dimethylpropyl)-6-[(3s)-3-methylpiperazin-1-yl]pyrimidin-2-amine Chemical compound C1CN[C@@H](C)CN1C1=CC(CC(C)(C)C)=NC(N)=N1 PCNMGQFUWWCGND-JTQLQIEISA-N 0.000 claims description 2
SGWPHUHXWXBNRO-CQSZACIVSA-N 4-(2-cyclopentylethyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(CCC2CCCC2)=NC(N)=N1 SGWPHUHXWXBNRO-CQSZACIVSA-N 0.000 claims description 2
YIKFBAFOIRPCQO-QGZVFWFLSA-N 4-(4-cyclohexylbutyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(CCCCC2CCCCC2)=NC(N)=N1 YIKFBAFOIRPCQO-QGZVFWFLSA-N 0.000 claims description 2
AESSVWUGGNHCOP-SNVBAGLBSA-N 4-(cyclopropylmethyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(CC2CC2)=NC(N)=N1 AESSVWUGGNHCOP-SNVBAGLBSA-N 0.000 claims description 2
YDFLKRYBTKDRQY-SNVBAGLBSA-N 4-[(3r)-3-(methylamino)pyrrolidin-1-yl]-6-(2-methylpropyl)pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(CC(C)C)=NC(N)=N1 YDFLKRYBTKDRQY-SNVBAGLBSA-N 0.000 claims description 2
SPLYXEJGYMQQQL-CYBMUJFWSA-N 4-[(3r)-3-(methylamino)pyrrolidin-1-yl]-6-(4-methylpentyl)pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(CCCC(C)C)=NC(N)=N1 SPLYXEJGYMQQQL-CYBMUJFWSA-N 0.000 claims description 2
XRODKUXJURUKFJ-SECBINFHSA-N 4-[(3r)-3-aminopyrrolidin-1-yl]-6-(cyclopropylmethyl)pyrimidin-2-amine Chemical compound C1[C@H](N)CCN1C1=CC(CC2CC2)=NC(N)=N1 XRODKUXJURUKFJ-SECBINFHSA-N 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
125000000168 pyrrolyl group Chemical group 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims 1
ATOPGMQXJOOTHB-SNVBAGLBSA-N 4-(2,2-dimethylpropyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(CC(C)(C)C)=NC(N)=N1 ATOPGMQXJOOTHB-SNVBAGLBSA-N 0.000 claims 1
OOBYWODJMYSVCV-OAHLLOKOSA-N 4-(3-cyclopentylpropyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(CCCC2CCCC2)=NC(N)=N1 OOBYWODJMYSVCV-OAHLLOKOSA-N 0.000 claims 1
FMMXBRFUTCEXOP-UHFFFAOYSA-N 4-(4-aminopiperidin-1-yl)-6-(cyclopropylmethyl)pyrimidin-2-amine Chemical compound C1CC(N)CCN1C1=CC(CC2CC2)=NC(N)=N1 FMMXBRFUTCEXOP-UHFFFAOYSA-N 0.000 claims 1
AESSVWUGGNHCOP-JTQLQIEISA-N 4-(cyclopropylmethyl)-6-[(3s)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound C1[C@@H](NC)CCN1C1=CC(CC2CC2)=NC(N)=N1 AESSVWUGGNHCOP-JTQLQIEISA-N 0.000 claims 1
SVTOCKLDPZCEGW-SNVBAGLBSA-N 4-[(3r)-3-(methylamino)pyrrolidin-1-yl]-6-propylpyrimidin-2-amine Chemical compound NC1=NC(CCC)=CC(N2C[C@@H](CC2)NC)=N1 SVTOCKLDPZCEGW-SNVBAGLBSA-N 0.000 claims 1
VMMSSXXGEPOROQ-SECBINFHSA-N 4-tert-butyl-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(C(C)(C)C)=NC(N)=N1 VMMSSXXGEPOROQ-SECBINFHSA-N 0.000 claims 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 1
230000037429 base substitution Effects 0.000 claims 1
CFBGXYDUODCMNS-UHFFFAOYSA-N cyclobutene Chemical compound C1CC=C1 CFBGXYDUODCMNS-UHFFFAOYSA-N 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
229940127557 pharmaceutical product Drugs 0.000 claims 1
JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 claims 1
125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 1
238000003971 tillage Methods 0.000 claims 1
229940119240 Histamine H4 receptor antagonist Drugs 0.000 abstract 1
239000003396 histamine H4 receptor antagonist Substances 0.000 abstract 1
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 43
229910052702 rhenium Inorganic materials 0.000 description 41
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 40
239000000203 mixture Substances 0.000 description 38
NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 36
206010057190 Respiratory tract infections Diseases 0.000 description 32
239000002904 solvent Substances 0.000 description 31
MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 28
238000006243 chemical reaction Methods 0.000 description 27
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 27
102000005962 receptors Human genes 0.000 description 27
108020003175 receptors Proteins 0.000 description 27
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
235000019439 ethyl acetate Nutrition 0.000 description 21
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
229960001340 histamine Drugs 0.000 description 19
239000000243 solution Substances 0.000 description 17
239000007858 starting material Substances 0.000 description 17
YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 16
239000010949 copper Substances 0.000 description 16
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
229910052739 hydrogen Inorganic materials 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
206010025135 lupus erythematosus Diseases 0.000 description 14
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 14
208000004454 Hyperalgesia Diseases 0.000 description 13
208000035154 Hyperesthesia Diseases 0.000 description 13
229910052786 argon Inorganic materials 0.000 description 13
230000000694 effects Effects 0.000 description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
206010039073 rheumatoid arthritis Diseases 0.000 description 12
206010052779 Transplant rejections Diseases 0.000 description 11
238000010438 heat treatment Methods 0.000 description 11
201000006417 multiple sclerosis Diseases 0.000 description 11
238000012360 testing method Methods 0.000 description 11
208000006673 asthma Diseases 0.000 description 9
239000012043 crude product Substances 0.000 description 9
210000003979 eosinophil Anatomy 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
208000022559 Inflammatory bowel disease Diseases 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
208000003251 Pruritus Diseases 0.000 description 8
239000012074 organic phase Substances 0.000 description 8
229920006395 saturated elastomer Polymers 0.000 description 8
201000000596 systemic lupus erythematosus Diseases 0.000 description 8
206010012438 Dermatitis atopic Diseases 0.000 description 7
206010065390 Inflammatory pain Diseases 0.000 description 7
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
201000008937 atopic dermatitis Diseases 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
229910052740 iodine Inorganic materials 0.000 description 7
230000007803 itching Effects 0.000 description 7
101150041968 CDC13 gene Proteins 0.000 description 6
208000002177 Cataract Diseases 0.000 description 6
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
206010009900 Colitis ulcerative Diseases 0.000 description 6
206010010744 Conjunctivitis allergic Diseases 0.000 description 6
208000011231 Crohn disease Diseases 0.000 description 6
201000004624 Dermatitis Diseases 0.000 description 6
208000003556 Dry Eye Syndromes Diseases 0.000 description 6
206010013774 Dry eye Diseases 0.000 description 6
208000004550 Postoperative Pain Diseases 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
201000004681 Psoriasis Diseases 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
206010039085 Rhinitis allergic Diseases 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
201000006704 Ulcerative Colitis Diseases 0.000 description 6
201000010105 allergic rhinitis Diseases 0.000 description 6
SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
230000002757 inflammatory effect Effects 0.000 description 6
208000004296 neuralgia Diseases 0.000 description 6
208000021722 neuropathic pain Diseases 0.000 description 6
238000010992 reflux Methods 0.000 description 6
208000023504 respiratory system disease Diseases 0.000 description 6
208000017520 skin disease Diseases 0.000 description 6
239000011734 sodium Substances 0.000 description 6
239000012453 solvate Substances 0.000 description 6
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 6
208000009935 visceral pain Diseases 0.000 description 6
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 5
KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 5
206010058019 Cancer Pain Diseases 0.000 description 5
206010020751 Hypersensitivity Diseases 0.000 description 5
208000019695 Migraine disease Diseases 0.000 description 5
208000024780 Urticaria Diseases 0.000 description 5
230000008859 change Effects 0.000 description 5
239000000460 chlorine Substances 0.000 description 5
208000030533 eye disease Diseases 0.000 description 5
210000003630 histaminocyte Anatomy 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
206010027599 migraine Diseases 0.000 description 5
201000008482 osteoarthritis Diseases 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
238000001514 detection method Methods 0.000 description 4
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
125000005843 halogen group Chemical group 0.000 description 4
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
239000011541 reaction mixture Substances 0.000 description 4
238000011160 research Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 3
KKFGZKBFBZYLJH-UHFFFAOYSA-N N-ethyl-N-propan-2-ylpropan-2-amine hydrazine Chemical compound C(C)(C)N(CC)C(C)C.NN KKFGZKBFBZYLJH-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000007815 allergy Effects 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
125000004069 aziridinyl group Chemical group 0.000 description 3
230000027455 binding Effects 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229910052802 copper Inorganic materials 0.000 description 3
238000010511 deprotection reaction Methods 0.000 description 3
GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 3
239000003480 eluent Substances 0.000 description 3
125000004494 ethyl ester group Chemical group 0.000 description 3
OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 3
238000005755 formation reaction Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000012535 impurity Substances 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
150000002923 oximes Chemical class 0.000 description 3
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
238000001525 receptor binding assay Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 2
YTSCCHQLULFXJD-SECBINFHSA-N 4-ethyl-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound NC1=NC(CC)=CC(N2C[C@@H](CC2)NC)=N1 YTSCCHQLULFXJD-SECBINFHSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
206010015150 Erythema Diseases 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000004384 Histamine H3 receptors Human genes 0.000 description 2
108090000981 Histamine H3 receptors Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
101001016858 Homo sapiens Histamine H4 receptor Proteins 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
201000009961 allergic asthma Diseases 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
244000309464 bull Species 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
239000013522 chelant Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000035605 chemotaxis Effects 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
210000004443 dendritic cell Anatomy 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000027119 gastric acid secretion Effects 0.000 description 2
229910052734 helium Inorganic materials 0.000 description 2
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical group [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
102000051809 human HRH4 Human genes 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000002955 isolation Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
206010034674 peritonitis Diseases 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
208000008423 pleurisy Diseases 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 2
ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
UEAYAIWNQQWSBK-GFCCVEGCSA-N (3r)-1-benzyl-n-methylpyrrolidin-3-amine Chemical compound C1[C@H](NC)CCN1CC1=CC=CC=C1 UEAYAIWNQQWSBK-GFCCVEGCSA-N 0.000 description 1
PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical group C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
DIZKLZKLNKQFGB-UHFFFAOYSA-N 1-methylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC1 DIZKLZKLNKQFGB-UHFFFAOYSA-N 0.000 description 1
LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
GQUMSCBPQXNIPT-VHSXEESVSA-N 2-amino-4-[(1R,2R)-2-phenylcyclopropyl]-1H-pyrimidin-6-one Chemical compound N1C(N)=NC(=O)C=C1[C@H]1[C@H](C=2C=CC=CC=2)C1 GQUMSCBPQXNIPT-VHSXEESVSA-N 0.000 description 1
JEHJSONFIXBLPG-UHFFFAOYSA-N 2-amino-6-(cyclopentylmethyl)-1h-pyrimidin-4-one Chemical compound NC1=NC(O)=CC(CC2CCCC2)=N1 JEHJSONFIXBLPG-UHFFFAOYSA-N 0.000 description 1
DPODJNAGSYHJMQ-UHFFFAOYSA-N 2-amino-6-cyclobutyl-1h-pyrimidin-4-one Chemical compound NC1=NC(O)=CC(C2CCC2)=N1 DPODJNAGSYHJMQ-UHFFFAOYSA-N 0.000 description 1
QDSSWFSXBZSFQO-UHFFFAOYSA-N 2-amino-6-ethyl-1h-pyrimidin-4-one Chemical compound CCC1=CC(=O)N=C(N)N1 QDSSWFSXBZSFQO-UHFFFAOYSA-N 0.000 description 1
FSYKBAWAYYELHH-UHFFFAOYSA-N 2-amino-6-propyl-1h-pyrimidin-4-one Chemical compound CCCC1=CC(=O)N=C(N)N1 FSYKBAWAYYELHH-UHFFFAOYSA-N 0.000 description 1
LTKWJTJJGNNDAY-UHFFFAOYSA-N 2-amino-6-tert-butyl-1h-pyrimidin-4-one Chemical compound CC(C)(C)C1=CC(O)=NC(N)=N1 LTKWJTJJGNNDAY-UHFFFAOYSA-N 0.000 description 1
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
WOPLHDNLGYOSPG-UHFFFAOYSA-N 2-butylbutanedioic acid Chemical compound CCCCC(C(O)=O)CC(O)=O WOPLHDNLGYOSPG-UHFFFAOYSA-N 0.000 description 1
FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
JPZOAVGMSDSWSW-UHFFFAOYSA-N 4,6-dichloropyrimidin-2-amine Chemical compound NC1=NC(Cl)=CC(Cl)=N1 JPZOAVGMSDSWSW-UHFFFAOYSA-N 0.000 description 1
YQMIEAVILICWMI-GFCCVEGCSA-N 4-(2-cyclopropylethyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(CCC2CC2)=NC(N)=N1 YQMIEAVILICWMI-GFCCVEGCSA-N 0.000 description 1
DOWAPMFLDPJVRQ-JTQLQIEISA-N 4-(2-cyclopropylethyl)-6-[(3s)-3-methylpiperazin-1-yl]pyrimidin-2-amine Chemical compound C1CN[C@@H](C)CN1C1=CC(CCC2CC2)=NC(N)=N1 DOWAPMFLDPJVRQ-JTQLQIEISA-N 0.000 description 1
PBNHURPUWHDQQS-GFCCVEGCSA-N 4-(cyclopentylmethyl)-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC(CC2CCCC2)=NC(N)=N1 PBNHURPUWHDQQS-GFCCVEGCSA-N 0.000 description 1
QIARZADPPQYKLV-QLFBSQMISA-N 4-[(3r)-3-(methylamino)pyrrolidin-1-yl]-6-[(1r,2r)-2-phenylcyclopropyl]pyrimidin-2-amine Chemical compound C1[C@H](NC)CCN1C1=CC([C@H]2[C@@H](C2)C=2C=CC=CC=2)=NC(N)=N1 QIARZADPPQYKLV-QLFBSQMISA-N 0.000 description 1
ICMSDAXNRCKFCV-JTQLQIEISA-N 4-[(3s)-3-methylpiperazin-1-yl]-6-(2,2,3,3-tetramethylcyclopropyl)pyrimidin-2-amine Chemical compound C1CN[C@@H](C)CN1C1=CC(C2C(C2(C)C)(C)C)=NC(N)=N1 ICMSDAXNRCKFCV-JTQLQIEISA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
AAINEFSCHYZRDZ-LLVKDONJSA-N 4-butyl-6-[(3r)-3-(methylamino)pyrrolidin-1-yl]pyrimidin-2-amine Chemical compound NC1=NC(CCCC)=CC(N2C[C@@H](CC2)NC)=N1 AAINEFSCHYZRDZ-LLVKDONJSA-N 0.000 description 1
LKQBPINQCZDQBX-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyrimidin-2-amine Chemical compound NC1=NC=CC(N2CCCC2)=N1 LKQBPINQCZDQBX-UHFFFAOYSA-N 0.000 description 1
JZVMJDFWTRHHPA-UHFFFAOYSA-N 7,8-dihydro-6h-thiopyrano[3,2-d]pyrimidine Chemical class N1=CN=C2CCCSC2=C1 JZVMJDFWTRHHPA-UHFFFAOYSA-N 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
YQDWBUAKCFLSNI-SSDOTTSWSA-N C(C)(C)(C)OC(NN[C@H]1CNCC1)=O Chemical compound C(C)(C)(C)OC(NN[C@H]1CNCC1)=O YQDWBUAKCFLSNI-SSDOTTSWSA-N 0.000 description 1
101100428016 Caenorhabditis elegans upp-1 gene Proteins 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010015943 Eye inflammation Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
102000006947 Histones Human genes 0.000 description 1
108010033040 Histones Proteins 0.000 description 1
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000254158 Lampyridae Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
239000007832 Na2SO4 Substances 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 description 1
241000219061 Rheum Species 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
235000006085 Vigna mungo var mungo Nutrition 0.000 description 1
240000005616 Vigna mungo var. mungo Species 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
VRJDXPZTXSCOPT-UHFFFAOYSA-N [Cl-].C(C)C(C[PH3+])CC Chemical compound [Cl-].C(C)C(C[PH3+])CC VRJDXPZTXSCOPT-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
XLUXHEZIGIDTCC-UHFFFAOYSA-N acetonitrile;ethyl acetate Chemical compound CC#N.CCOC(C)=O XLUXHEZIGIDTCC-UHFFFAOYSA-N 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
150000001345 alkine derivatives Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000732 arylene group Chemical group 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
229910000062 azane Inorganic materials 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
235000015111 chews Nutrition 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000013058 crude material Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
150000001924 cycloalkanes Chemical class 0.000 description 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000002542 deteriorative effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical compound C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
VHKHNUDQGCOFAL-UHFFFAOYSA-N ethyl 4-ethyl-3-oxohexanoate Chemical compound CCOC(=O)CC(=O)C(CC)CC VHKHNUDQGCOFAL-UHFFFAOYSA-N 0.000 description 1
SSDZYLQUYMOSAK-UHFFFAOYSA-N ethynylcyclohexane Chemical group C#CC1CCCCC1 SSDZYLQUYMOSAK-UHFFFAOYSA-N 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000000499 gel Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
229940071870 hydroiodic acid Drugs 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
CWFODZHVCJONPU-RXMQYKEDSA-N methyl-[(3r)-pyrrolidin-3-yl]carbamic acid Chemical compound OC(=O)N(C)[C@@H]1CCNC1 CWFODZHVCJONPU-RXMQYKEDSA-N 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
VSPPONOIKZXUBJ-UHFFFAOYSA-N n,n-diethylethanamine;oxolane Chemical compound C1CCOC1.CCN(CC)CC VSPPONOIKZXUBJ-UHFFFAOYSA-N 0.000 description 1
OXKUGIFNIUUKAW-UHFFFAOYSA-N n,n-dimethylformamide;hydrazine Chemical compound NN.CN(C)C=O OXKUGIFNIUUKAW-UHFFFAOYSA-N 0.000 description 1
OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
229940073020 nitrol Drugs 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003349 osteoarthritic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008855 peristalsis Effects 0.000 description 1
150000004714 phosphonium salts Chemical class 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000012088 reference solution Substances 0.000 description 1
MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical group [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000002437 synoviocyte Anatomy 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
XSOKHXFFCGXDJZ-UHFFFAOYSA-N telluride(2-) Chemical compound [Te-2] XSOKHXFFCGXDJZ-UHFFFAOYSA-N 0.000 description 1
LGEWGFOMLJQHLL-ZJUUUORDSA-N tert-butyl (4ar,7ar)-2,3,4,4a,5,6,7,7a-octahydropyrrolo[3,4-b]pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]2CNC[C@H]12 LGEWGFOMLJQHLL-ZJUUUORDSA-N 0.000 description 1
SJMYWORNLPSJQO-UHFFFAOYSA-N tert-butyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C)(C)C SJMYWORNLPSJQO-UHFFFAOYSA-N 0.000 description 1
XYKYUXYNQDXZTD-MRVPVSSYSA-N tert-butyl n-methyl-n-[(3r)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)[C@@H]1CCNC1 XYKYUXYNQDXZTD-MRVPVSSYSA-N 0.000 description 1
JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
RSPCKAHMRANGJZ-UHFFFAOYSA-N thiohydroxylamine Chemical compound SN RSPCKAHMRANGJZ-UHFFFAOYSA-N 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000004704 ultra performance liquid chromatography Methods 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

TW097145757A 2007-11-30 2008-11-26 2-aminopyrimidine derivatives TW200936570A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP07381074		2007-11-30

Publications (1)

Publication Number	Publication Date
TW200936570A true TW200936570A (en)	2009-09-01

Family

ID=39197144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW097145757A TW200936570A (en)	2007-11-30	2008-11-26	2-aminopyrimidine derivatives

Country Status (5)

Country	Link
AR (1)	AR069480A1 (es)
CL (1)	CL2008003537A1 (es)
PE (1)	PE20091035A1 (es)
TW (1)	TW200936570A (es)
WO (1)	WO2009068512A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE602007008545D1 (de)	2006-03-31	2010-09-30	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
CN101511190A (zh)	2006-07-11	2009-08-19	詹森药业有限公司	组胺h4受体的苯并呋喃并-和苯并噻吩并嘧啶调节剂
TW200904437A (en)	2007-02-14	2009-02-01	Janssen Pharmaceutica Nv	2-aminopyrimidine modulators of the histamine H4 receptor
TW200924781A (en)	2007-09-14	2009-06-16	Janssen Pharmaceutica Nv	Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
US8841287B2 (en)	2008-06-12	2014-09-23	Janssen Pharmaceutica N.V.	Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor
US9371311B2 (en)	2008-06-30	2016-06-21	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyrimidine derivatives
EP2201982A1 (en)	2008-12-24	2010-06-30	INSERM (Institut National de la Santé et de la Recherche Médicale)	Histamine H4 receptor antagonists for the treatment of vestibular disorders
EP2493895B1 (en)	2009-10-29	2017-04-26	Vectura Limited	N-containing heteroaryl derivatives as jak3 kinase inhibitors
US8901146B2 (en) *	2009-12-23	2014-12-02	Medicis Pharmaceutical Corporation	Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists
BR112014003496B1 (pt)	2011-08-18	2022-02-22	Nippon Shinyaku Co., Ltd	Derivado heterocíclico, usos do mesmo e composição farmacêutica
WO2013182711A1 (en)	2012-06-08	2013-12-12	Sensorion	H4 receptor inhibitors for treating tinnitus
WO2014010748A1 (en) *	2012-07-10	2014-01-16	Shionogi & Co., Ltd.	Cyclopropane derivative having bace1 inhibiting activity
PL2964229T3 (pl)	2013-03-06	2020-05-18	Janssen Pharmaceutica Nv	Benzoimidazol-2-ilo pirymidynowe modulatory receptora histaminowego H<sub>4</sub>
WO2017160922A1 (en) *	2016-03-16	2017-09-21	Kalyra Pharmaceuticals, Inc.	Analgesic compounds
WO2017160925A1 (en) *	2016-03-16	2017-09-21	Kalyra Pharmaceuticals, Inc.	Analgesic compounds
GB201817047D0 (en)	2018-10-19	2018-12-05	Heptares Therapeutics Ltd	H4 antagonist compounds
GB202005858D0 (en) *	2020-04-22	2020-06-03	Heptares Therapeutics Ltd	H4 Antagonist compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1505064A1 (en) *	2003-08-05	2005-02-09	Bayer HealthCare AG	2-Aminopyrimidine derivatives
WO2005054239A1 (en) *	2003-12-05	2005-06-16	Bayer Healthcare Ag	2-aminopyrimidine derivatives
RU2008114378A (ru) *	2005-09-13	2009-10-20	Палау Фарма, С.А. (Es)	Производные 2-аминопиримидина как модуляторы активности н4-рецептора гистамина
NL2000323C2 (nl) *	2005-12-20	2007-11-20	Pfizer Ltd	Pyrimidine-derivaten.
EP2066645A2 (en) *	2006-09-12	2009-06-10	UCB Pharma S.A.	2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
US7985745B2 (en) *	2006-10-02	2011-07-26	Abbott Laboratories	Method for pain treatment
TW200904437A (en) *	2007-02-14	2009-02-01	Janssen Pharmaceutica Nv	2-aminopyrimidine modulators of the histamine H4 receptor

2008
- 2008-11-25 WO PCT/EP2008/066110 patent/WO2009068512A1/en not_active Ceased
- 2008-11-25 AR ARP080105118A patent/AR069480A1/es unknown
- 2008-11-25 PE PE2008001971A patent/PE20091035A1/es not_active Application Discontinuation
- 2008-11-26 TW TW097145757A patent/TW200936570A/zh unknown
- 2008-11-27 CL CL2008003537A patent/CL2008003537A1/es unknown

Also Published As

Publication number	Publication date
CL2008003537A1 (es)	2009-03-06
PE20091035A1 (es)	2009-07-16
WO2009068512A1 (en)	2009-06-04
AR069480A1 (es)	2010-01-27

Publication	Publication Date	Title
TW200936570A (en)	2009-09-01	2-aminopyrimidine derivatives
TWI879811B (zh)	2025-04-11	作為免疫調節劑之吡啶并[3,2-d]嘧啶化合物
JP6948659B1 (ja)	2021-10-13	ピリダジニルチアアゾールカルボキシアミド化合物
CN112135824B (zh)	2024-11-05	作为免疫调节剂的杂环化合物
JP6059723B2 (ja)	2017-01-11	４−（８−メトキシ−１−（（１−メトキシプロパン−２−イル）−２−（テトラヒドロ−２Ｈ−ピラン−４−イル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−７−イル）−３，５−ジメチルイソオキサゾールおよびブロモドメイン阻害剤としてのその使用
TWI429440B (zh)	2014-03-11	４－胺基－嘧啶衍生物類
TW201113285A (en)	2011-04-16	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2022271794A1 (en)	2024-01-04	Substituted heterocyclic compounds
TW201204730A (en)	2012-02-01	Pyrrolopyrazine kinase inhibitors
TW200940529A (en)	2009-10-01	2-amino-pyrimidine derivatives
CN105228625A (zh)	2016-01-06	大环rip2激酶抑制剂
TWI487697B (zh)	2015-06-11	作為組織胺ｈ受體拮抗劑之胺基烷基嘧啶衍生物類
CN118772176A (zh)	2024-10-15	一种嘧啶并芳环化合物及其制备方法和用途
TW200951136A (en)	2009-12-16	Furo[3,2-d]pyrimidine derivatives
TW201026701A (en)	2010-07-16	Pyrazolopyrimidine derivatives as histamine H4 receptor antagonists
TW200934783A (en)	2009-08-16	Furo[3,2-d]pyrimidine derivatives
JP2020502081A (ja)	2020-01-23	Ｔｎｆ活性のモジュレーターとしての置換ベンゾイミダゾール誘導体
TW201041867A (en)	2010-12-01	Piperidin-pyrimidine derivatives as histamine H4 receptor antagonists
HK1149003B (en)	2013-11-08	4-aminopyrimidine derivatives as histamine h4 receptor antagonists